Abstract
When writing a chapter on immunosuppression for pancreas transplant recipients in 1986/87 one has to realize that the drug cyclosporin (CS) plays an important and major role in terms of a powerful immunosuppressive agent with regard to all protocols applied world-wide at the present time. At the moment, therefore, there appears to be no room for an exclusive use of conventional immunosuppressive therapy consisting of steroids and azathioprine in pancreatic transplantation. At the same time one has to state that an immunosuppressive protocol (including cyclosporin) in terms of a well-controlled large clinical trial with special emphasis on the particular situation of clinical pancreatic transplantation has not been worked out or even widely tested so far. Probably, the relatively small number of recipients transplanted at a few institutions are the major hint for the performance of such a clinical trial.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Land W: Optimal use of cyclosporin. An attempt at evaluation. In: Optimal use of Sand- immun in Organ Transplantation, ed. W. Land. Sandoz Ltd Basel and Springer Verlag Berlin, Heidelberg, 1987.
Kahan BB: Individualization of cyclosporin therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40: 457, 1985.
Thiel G: Personal communication.
Sollinger HW, Deierhoi M, Kalayoglu M, Belzer EO: Sequential antilymphocyte globulin- cyclosporin therapy in cadaveric renal transplantation. Transpl Proc 18: 16, 1986.
Sollinger HW, Kalayoglu M, Hoffman M, Belzer FO: Quadruple immunosuppressive therapy in whole pancreas transplantation. Transpl Proc 19: 2297, 1987.
Sutherland DER, Goetz EC, Najarian JS: Improved pancreas graft survival by use of multiple drug combination immunotherapy. Transpl Proc 18: 1770, 1986.
Quesniaux V: The use of monoclonal antibodies to probe the surface of cyclosporines. Transpl Proc 18: (Suppl 5) 111, 1986.
Castro LA, Landgraf R, Hillebrand G, Land W: Causes of renal graft dysfunction in diabetics after simultaneous pancreas and kidney transplantation. Transpl Proc 18: 1733, 1986.
Groth CG: Personal communication.
Sutherland DER, Moudry K: Pancreas transplant registry. Transpl Proc 18: 1739, 1986.
Tyden G, Brattstrom C, Gunnarsson R, Lundgren G, Ost L, Ostman J, Groth CG: Metabolic control 4 months to 4 years after pancreatic transplantation with special reference to the role of cyclosporin. Transpl Proc 19: 1987.
Dubernard JM, Faures JW, Gelet A, Martin X, Lefrancois N, Monti L, Similon B, Manzan K, Toraine JW, Traeger J: Simultaneous pancreas and kidney transplantation: long-term results and technical discussion. Transpl Proc 19: 1987.
II. Internat. workshop on clinical pancreatic transplantation: Munich, Spitzingsee, December 1986. Discussion comments by: Corry R, Dubernard JM, Groth CG, Land W, Margreiter R, Sollinger H, Sutherland DER. Papers published in Transpl Proc vol. 1987
Land W, Hillebrand G, Illner WD, Abendroth D, Haucke E, Schleibner S, Hammer C, Raceberg J: First clinical experience with a new TCR/CD3 monoclonal antibody (BMA031) in kidney transplant patients. Transplant Int 1: 116, 1988.
Squifflet JP, Sutherland DER, Rynasiewicz JJ, Field J, Heil J, Najarian JS: Combined immunosuppressive therapy with cyclosporin A and azathioprine. Transplantation 34: 315 – 318, 1982.
Simmons RL, Canafax DM, Strand M, Ascher NL, Payne WD, Sutherland DER, Najarian JS: Management and prevention of cyclosporin nephrotoxicity after renal transplantation: use of low doses of cyclosporin, azathioprine, and prednisone. Transpl Proc 17: 266 – 275, 1985.
Sutherland DER, Goetz FC, Najarian JS: Improved pancreas graft survival rates by use of multiple drug combination immunotherapy. Transpl Proc 18: 1770 – 1773, 1986.
Bolman RN et al. J Heart Transplantation 4: 315, 1985.
St. Cyr JA, Elick B, Freese D et al.: Use of triple therapy and percutaneous needle biopsy to minimize graft failure following liver transplantation. Transpl Proc 19: 2451, 1987.
Sollinger HW, Kalayoglu M, Hoffman RM: Quadruple immunosuppressive therapy in whole pancreas transplantation. Transpl Proc 19: 2297 – 2299, 1987.
Sutherland DER, Kendall DM, Moudry KC, Navarro X, Kennedy WR, Ramsay RC, Steffes MW, Mauer SM, Goetz FC, Dunn DL, Najarian JS: Pancreas transplantation in nonuremic, Type I diabetic recipients. Surgery 104: 453 – 464, 1988.
DeFrancisco AM, Mauer SM, Steffes MW, Goetz FC, Najarian JS, Sutherland DER: The effect of cyclosporin on native renal function in nonuremic diabetic recipients of pancreas transplants. J Diab Compl 1: 128 – 131, 1987.
Sutherland DER, Moudry KC: Report of the international pancreas transplant registry. In: Terasaki PI (ed) Clinical Transplants - 1987, pp. 63-101. UCLA Press, Los Angeles.
Sutherland DER, Goetz FC, Moudry KC, Najarian JS: Pancreatic transplantation - A single institution’s experience. Diab Nutr and Metabolisml: 57 – 66, 1988.
Prieto M, Sutherland DER, Goetz FC, Rosenberg ME, Najarian JS: Pancreas transplant results according to the technique of duct management: bladder versus enteric drainage. Surgery 102: 680 – 691, 1987.
Margreiter R, Klima G, Bosmuller C: Rejection of kidney and pancreas after pancreatic- kidney transplantation. Diabetes (Suppl.) 37: 74 – 81, 1988.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Land, W. (1989). Immunosuppression for pancreas transplant recipients. In: Dubernard, J.M., Sutherland, D.E.R. (eds) International Handbook of Pancreas Transplantation. Developments in Surgery, vol 10. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1083-6_9
Download citation
DOI: https://doi.org/10.1007/978-94-009-1083-6_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6977-9
Online ISBN: 978-94-009-1083-6
eBook Packages: Springer Book Archive